Colorectal Cancer: UNICORN Study on Targeted Preoperative Treatments

We are studying short-course targeted treatments for patients with resectable colorectal cancer to see if they improve treatment response and quality of life. This trial aims to understand the safety and effectiveness of these treatments before surgery.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Amivantamab
Amivantamab is a substance that targets specific proteins on certain lung cancer cells to help control advanced non-small-cell lung cancer with EGFR exon 20 mutations.
Durvalumab
Durvalumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein tumors use to hide.
Nivolumab
Nivolumab is a substance that helps the immune system recognize and attack certain cancers.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Botensilimab
Balstilimab
Jnj-61186372

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centro Di Riferimento Oncologico Di Aviano
Oncologia Medica
Aviano-Castello, Italy
Fondazione Poliambulanza
Oncologico
Brescia, Italy
ASST Grande Ospedale Metropolitano Niguarda
S.C. Oncologia
Bresso, Italy

Sponsor: Gruppo Oncologico Del Nord Ovest
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.